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Abstract
Aims/hypothesis This study aimed to examine the association
between copeptin (a surrogate marker of arginine vasopressin)
and incident stroke, CHD and cardiovascular mortality in
older men with and without diabetes.
Methods We conducted a prospective study of 3536men aged
60–79 years who were followed for an average of 13 years.
During this period, there were 437 major CHD events (fatal
and non-fatal myocardial infarction [MI]), 323 stroke events
(fatal and non-fatal) and 497 cardiovascular disease (CVD)
deaths. Prevalent diabetes was defined on the basis of a history
of doctor-diagnosed diabetes or fasting blood glucose
≥7.0 mmol or HbA1c ≥6.5% (48 mmol/mol) (n=428).
Results No association was seen between copeptin and
incident stroke or CVD mortality in men without diabetes
after adjustment for conventional cardiovascular risk factors,
renal dysfunction, and insulin and N-terminal pro B-type
natriuretic peptide levels. In contrast, elevated copeptin levels
were associated with an increased risk of stroke and CVD
mortality in men with diabetes after these adjustments.
Compared with those in the lowest tertile of copeptin, men
in the top tertile had adjusted relative HRs for stroke and CVD
death of 2.34 (95% CI 1.04, 5.27) and 2.21 (1.12, 4.36),
respectively. The risk of stroke and CVD mortality remained
increased after the exclusion of men with prevalent stroke or
MI. Higher levels of copeptin were associated with increased
risk of CHD in the diabetic and non-diabetic groups, but these
associations were attenuated after exclusion of individuals
with a previous stroke or MI.
Conclusions/interpretation Copeptin was independently
associated with an increased risk of incident stroke and
CVD mortality in men with diabetes, but not in men without
diabetes. Targeting the arginine vasopressin system might
have beneficial effects on CVD mortality and stroke risk in
older men with diabetes.
Keywords Cardiovascular mortality . Copeptin . Coronary
heart disease . Diabetes . Epidemiology . Stroke
Abbreviations
AVP Arginine vasopressin
CRP C-reactive protein
CVD Cardiovascular disease
eGFR Estimated GFR
MI Myocardial infarction
NT-proBNP N-terminal pro B-type natriuretic peptide
SGLT2 Sodium-glucose transporter 2
Introduction
Cardiovascular disease (CVD) is the leading cause of death in
patients with type 2 diabetes mellitus [1, 2]. It is well
established that type 2 diabetes is a major risk factor for
CVD, including myocardial infarction (MI) and stroke
[1–3]. Type 2 diabetes has been associated with a two- to
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sixfold increase in the risk of stroke compared with no
diabetes [3]. The reduction of cardiovascular risk in
individuals with type 2 diabetes is thus of paramount
importance.
Arginine vasopressin (AVP), also known as antidiuretic
hormone, is a nonapeptide that is produced in the
hypothalamus. AVP is released from the neurohypophysis to
promote renal water conservation, and plays important roles in
the regulation of the cardiovascular system, water electrolyte
balance and many functions of the central nervous system
[4, 5]. Vasopressin receptors are widely distributed throughout
the brain [6]. They are present in neurons, astrocytes and their
perivascular processes, blood vessel endothelial and smooth
muscle cells, and the choroid plexus. These locations suggest
that vasopressin may participate in regulating vascular
resistance in the cerebral circulation and water homeostasis
in the brain [6]. Human and animal studies have indicated that
the AVP system may play a role in glucose homeostasis,
insulin resistance, and lipid and fat metabolism [7–9], and
vasopressin has been reported to be elevated in patients with
type 2 diabetes [10]. However, plasma AVP is difficult to
measure because of its instability and short half-life [11].
Plasma carboxy-terminal pro-vasopressin (copeptin), the
C-terminal part of the AVP precursor peptide, is stable in
serum and plasma, making it a more convenient biomarker.
Indeed, copeptin has been established as a reliable marker of
the circulating AVP concentration in routine clinical practice
[11].
Copeptin is known to be raised in individuals with type 2
diabetes and has been associated with the development of
diabetes [12, 13]. Raised copeptin has also been associated
with CVD mortality in patients with type 2 diabetes
complicated by end-stage renal disease or acute MI, as well
as in individuals with diabetes who are treated in primary care
and those in the general population [14–18]. Stroke incidence
rises steeply with age and the number of older people with
type 2 diabetes is increasing. Attention has therefore turned to
identifying new therapeutic approaches to preventing stroke in
individuals with type 2 diabetes [19]. Copeptin has been
shown to predict incident stroke in diabetic patients
undergoing haemodialysis [15], but its ability to predict
incident stroke events in individuals with and without diabetes
among the older general population has not yet been assessed.
To evaluate these issues, we examined the association
between copeptin and incident stroke, as well as CHD events
(fatal and non-fatal) and CVD mortality, in men with and
without diabetes.
Methods
Participants The British Regional Heart Study is a
prospective study of CVD involving 7735 men aged
40–59 years drawn from general practice in each of 24
British towns, with participants recruited between 1978
and 1980 [20]. The population is socioeconomically
representative of British men, but is predominantly comprised
of white Europeans (>99%). In 1998–2000, all of the
surviving men, then aged 60–79 years (mean age 68.7 years),
were invited for a 20th year follow-up examination. The men
completed a questionnaire, which included questions on their
medical history and lifestyle. They were also asked to fast for
a minimum of 6 h, during which time they were instructed to
drink only water, and to attend for various measurements (see
below) at a prespecified time between 08:00 and 18:00 hours.
All men were asked to provide a blood sample, which was
collected using the Sarstedt Monovette system (Sarstedt,
Numbrecht, Germany). The samples were frozen and stored
at –20°C on the day of collection and transferred in batches for
storage at –70°C until analysis, which was carried out after no
more than one freeze–thaw cycle. The men were asked
whether a doctor had ever told them that they had angina or
MI (heart attack, coronary thrombosis) or stroke, and to take
anymedication theywere taking to the examination session. A
total of 4252 men (77% of survivors) underwent examination
and 4094 provided blood samples.
Cardiovascular risk factors Anthropometric measurements,
including body weight, height and waist circumference, were
taken. Participants were measured standing in light clothing
without shoes. Height was measured using a Harpenden
stadiometer (Holtain, Crymych, UK) to the last complete
0.1 cm, and weight was measured using a Soehnle digital
electronic scale (Soehnle, Murrhardt, Germany) to the last
complete 0.1 kg. BMI (weight/height2 [kg/m2]) was
calculated for each participant. Waist circumference was
measured in duplicate using an insertion tape (CMS,
London, UK) at the midpoint between the iliac crest and
the lower rib margins measured at the sides. Details of
measurements and classification methods for smoking status,
physical activity, social class and BP have been previously
described [21, 22].
Moderate drinking was defined as 21–34 drinks/week
(3–4 drinks/day), while heavy drinking was defined as those
reporting drinking ≥35 drinks/week (≥5 drinks/day). Plasma
glucose was measured with a glucose oxidase method using a
Falcor 600 automated analyser (A. Menarini Diagnostics,
Wokingham, UK) [23]. Serum insulin was measured using
an ELISA assay (R&D systems, Oxford UK) that did not
cross-react with proinsulin [24]. Triacylglycerol, glucose and
insulin concentrations were adjusted for the effects of fasting
duration and time of day [22]. Insulin resistance was estimated
according to HOMA [25]. The estimated (e)GFR (a measure
of renal function) was calculated from serum creatinine using
the modification of diet in renal disease equation developed by
Levey et al [26]. Chronic kidney disease was defined as eGFR
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<60 ml min–1 1.73 m–2. Von Willebrand factor antigen was
measured using an ELISA antigen (DAKO, High Wycombe,
UK). C-reactive protein (CRP) was assayed by ultra-sensitive
nephelometry (Dade Behring, Milton Keynes, UK).
Prevalent diabetesMenwith a doctor’s diagnosis of diabetes,
those with fasting glucose of ≥7 mmol/l (WHO criteria) or
those with HbA1c ≥6.5% (48 mmol/mol) were considered to
have prevalent diabetes [27].
Copeptin and N-terminal pro B-type natriuretic peptide
(NT-proBNP) Serum levels of copeptin and NT-proBNP
were measured using manufacturers’ calibrators and controls
in accordance with their instructions. NT-proBNP was
determined using the Elecsys 2010 electrochemiluminescence
method (Roche Diagnostics, Burgess Hill, UK) [28]. The
lower limit of sensitivity was 5 ng/l. Low control CV was
6.7% and high control CV was 4.9%. Copeptin was measured
using an ultra-sensitive method on a BRAHMS Kryptor
Compact Plus (BRAHMS, Bottisham, UK). The lower limit
of sensitivity was 0.9 pmol/l. Low control CV was 4.7% and
high control CV was 4.6%. We examined copeptin levels by
the time of examination. Although copeptin levels were
highest at 13:00 hours (geometric mean 4.95 pmol/l,
interquartile range [IQR] 2.76–8.11 pmol/l), there was no
consistent significant diurnal variation throughout the day.
For example, the mean copeptin level between 09:00 and
10:00 hours (3.97 pmol/l [IQR 2.50–6.58 pmol/l]) was similar
to that between 12:00 and 13:00 hours (3.94 pmol/l [IQR
2.49–6.49 pmol/l]) and between 17:00 and 18:00 hours
(3.94 pmol/l [IQR 2.61–6.32 pmol/l]).
Follow-up All of the men were followed for cardiovascular
morbidity from the initial examination (1978–1980), and
follow-up was achieved for 99% of the cohort [29]. In the
present analyses, all-cause mortality and morbidity events
were based on follow-up from re-screening in 1998–2000 at
a mean age of 60–79 years to July 2012, a mean follow-up
period of 13 years (range 12–14 years). Information on death
was collected through National Health Service registers, in
which the participants were flagged for follow-up [30].
During the follow-up period, changing diagnostic criteria
were taken into account by using both ICD-9 and ICD-10
codes. For the present paper, CHD deaths were defined as
ICD-9 codes 410–414 or ICD-10 codes I20–I25. Stroke
deaths were defined as ICD-9 codes 430–438 or ICD-10
codes I60–I69. Non-fatal stroke events were defined as those
that resulted in a neurological deficit that was present for more
than 24 h. Evidence regarding non-fatal stroke and MI events
was obtained by ongoing reports from general practitioners,
by biennial reviews of patients’ practice records (including
hospital and clinic correspondence) through to the end of the
study period and from repeated questionnaires sent to
surviving participants after the initial examination.
Pre-existing CVD was defined as a history of a doctor’s
diagnosis ofMI or stroke. Patient recall of a doctor’s diagnosis
of CHD has been shown to be a valid measure of recording
disease in this study population [31]; the K statistic for
comparing record reviews with patients’ recall of CHD was
0.82 [31].
Statistical methods The distribution of copeptin levels was
skewed and natural log transformation was therefore used.
Cox’s proportional hazards model was used to assess
multivariate-adjusted HRs (relative risk) in a comparison of
three copeptin groups (<3.35, 3.35–6.95 and ≥6.96 pmol/l), as
well as in a 1 unit increase in loge copeptin. As men with
diabetes showed significantly higher levels of copeptin
than men without diabetes (mean 6.96 pmol/l [IQR
2.90–8.63 pmol/l] vs 3.34 pmol/l [IQR 2.40–5.88 pmol/l],
respectively), the cut-offs for the three groups were based on
the tertile distribution in men with diabetes to achieve
sufficient numbers in each group and then applied to those
without diabetes. Thus, the number of men in each of the three
groups was not equally distributed in those without diabetes.
In multivariate analyses, smoking (never, long-term
ex-smokers [>15 years], recent ex-smokers [<15 years] and
current smokers), social class (manual vs non-manual work),
physical activity (four groups), heavy drinking (yes/no),
prevalent MI and prevalent stroke were fitted as categorical
variables; CRP, eGFR, BMI, systolic BP, HDL-cholesterol,
HOMA-IR, blood glucose and NT-proBNP were fitted as
continuous variables. Adjustment for diurnal variation was
carried out by fitting the time of examination as three groups:
morning (9:00–13:00 hours), lunchtime (13:00 hours) and
afternoon (14:00–18:00 hours). A test for interaction was
carried out by fitting the interaction term ‘loge copeptin ×
prevalent diabetes (yes/no)’ into the model. A sensitivity
analysis was performed excluding men with prevalent MI or
stroke. p<0.05 was used to indicate statistical significance.
Study sample Copeptin measurements were available for
3663 men. Because heart failure is known to raise AVP
(copeptin) and copeptin may be a marker of the severity of
heart failure [32], we excluded 127 men with a history of heart
failure, leaving 3536 men for analysis.
Results
During the mean follow-up period of 13 years, the 3536 men
without heart failure experienced 437 major CHD events
(11.3/1000 person-years) and 323 major stroke events
(8.6/1000 person-years), with 497 deaths from cardiovascular
causes.
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Table 1 shows baseline characteristics by the three copeptin
groups in men with and without diabetes. Copeptin was
strongly related to BMI, renal function, HOMA-IR and
NT-proBNP in both the diabetic and non-diabetic groups.
The prevalence of stroke and MI was highest in those with
elevated copeptin.
Copeptin and incident CVD in men without diabetes
Elevated copeptin was associated with a significantly
increased risk of CHD events after adjustment for age
(Table 2). Further adjustment for CVD risk factors including
smoking, physical activity, social class, BMI, HDL-C, systolic
BP, antihypertensive treatment, eGFR, prevalent MI,
prevalent stroke, CRP, HOMA-IR and blood glucose (Model
2) attenuated the association, although it remained statistically
significant. However, the association was markedly reduced
after the exclusion of men with prevalent CVD (MI or stroke).
There was no significant association between copeptin and
incident stroke or CVD mortality after adjustment for these
CVD risk factors in Model 2. Additional adjustment for
diurnal variations made little difference to the findings.
Copeptin and incident CVD in men with diabetes In
contrast to men without diabetes, copeptin was significantly
associated with incident stroke and CVD mortality among
men with diabetes, even after adjustment for cardiovascular
risk factors and upon the exclusion of men with prevalent
CVD (Table 3). Additional adjustment for the use of ACE
inhibitors made little difference to these findings. A formal
test for interaction confirmed a significant difference in
the relationship between copeptin and risk of stroke and
CVD between men with and without diabetes after the
exclusion of men with MI or stroke (p=0.01 and p=0.02,
respectively).
No association was seen between copeptin and the risk of
major CHD events (fatal or non-fatal) in men with diabetes
after adjustment for established cardiovascular risk factors
(Table 3). In contrast to the significant interaction seen for
stroke and CVDmortality, there was no significant interaction
for CHD events between men with and without diabetes
(p=0.81). Additional adjustment for diurnal variation made
no material difference to the findings. When examined in
relation to non-fatal (n=19) and fatal (n=48) CHD events, a
Table 2 Incidence rates/1000
person-years and adjusted HRs
(95% CIs) for CVD endpoints by
copeptin levels in 3108 men with
no prevalent diabetes and no heart
failure
Incidence Copeptin (pmol/l)a 1 unit increase
in loge copeptin
p trend
<3.35
(n = 1376)
3.35–6.95
(n= 1151)
≥6.96
(n= 581)
CHD (n= 370)
Rate/1000
person-years (n)
8.5 (134) 11.4 (146) 15.2 (90)
Age-adjusted HR 1.00 1.27 (1.01, 1.61) 1.68 (1.28, 2.19) 1.23 (1.00, 1.40) 0.002
Model 1 1.00 1.24 (0.97, 1.57) 1.45 (1.10, 1.92) 1.15 (1.01, 1.30) 0.04
Model 2 1.00 1.21 (0.95, 1.55) 1.36 (1.01, 1.83) 1.12 (0.98, 1.27) 0.10
Model 2a 1.00 1.24 (0.94, 1.62) 1.22 (0.87, 1.71) 1.04 (0.91, 1.19) 0.54
Stroke (n = 272)
Rate/1000
person-years (n)
7.2 (111) 8.2 (101) 10.5 (60)
Age-adjusted HR 1.00 1.07 (0.81, 1.40) 1.37 (1.00, 1.84) 1.12 (0.97, 1.29) 0.13
Model 1 1.00 1.00 (0.76, 1.32) 1.16 (0.84, 1.62) 1.03 (0.90, 1.17) 0.65
Model 2 1.00 0.99 (0.75, 1.31) 1.13 (0.80, 1.59) 1.03 (0.90, 1.17) 0.71
Model 2a 1.00 1.12 (0.82, 1.53) 1.26 (0.79, 1.71) 1.05 (0.90, 1.24) 0.52
CVD death (n= 419)
Rate/1000
person-years (n)
9.2 (144) 13.2 (168) 18.1 (107)
Age-adjusted HR 1.00 1.31 (1.05, 1.64) 1.82 (1.41, 2.33) 1.29 (1.14, 1.46) 0.005
Model 1 1.00 1.18 (0.93, 1.48) 1.43 (1.10, 1.86) 1.13 (1.00, 1.28) 0.05
Model 2 1.00 1.15 (0.91, 1.45) 1.28 (0.97, 1.69) 1.08 (0.95, 1.22) 0.22
Model 2a 1.00 1.19 (0.96, 1.60) 1.02 (0.73, 1.43) 0.97 (0.86, 1.11) 0.62
a Cut-offs based on the tertile distribution in men with diabetes
Model 1: adjusted for age, smoking, physical activity, heavy drinking, social class, BMI, HDL-C, systolic BP,
antihypertensive treatment, prevalent MI and prevalent stroke
Model 2: Model 1 +CRP+HOMA-IR+ blood glucose + eGFR
Model 2a: adjusted for Model 1 and excluding men with prevalent MI/stroke (n= 353; 11.4%)
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non-significant inverse association between copeptin levels
and non-fatal events was seen, and a positive association was
seen with fatal events after adjustment for factors in Model 3,
although the numbers were small and the increased risk was
not significant (adjusted HR 1.68 [95% CI 0.72, 3.92]; top
third vs lowest third). Although CHD deaths accounted for
more than 50% of all CVD deaths (n=48/78), the increased
risk of CVD mortality was largely due to stroke or other CVD
deaths (adjusted HR 4.64 [95% CI 1.27, 16.74]).
Discussion
In this study of older men, copeptin was significantly
associated with incident stroke and CVD mortality in
men with diabetes, after adjustment for established CVD
risk factors and following the exclusion of men with MI
or stroke, and in keeping with the markedly elevated
copeptin levels in this patient group. In contrast, we did
not find any significant association between copeptin and
incident stroke or CVD mortality in men without diabetes
after adjustment for established CVD risk factors.
Copeptin was positively associated with incident CHD
in men both with and without diabetes, but these associ-
ations were to a large extent associated with pre-existing
CVD as the exclusion of individuals with MI/stroke atten-
uated the association in both groups. Our findings confirm
previous studies reporting an association between
copeptin and CVD in diabetes [14–18], and extend the
findings to stroke incidence in individuals both with and
without diabetes in the general population. We were able
to take into account a wide range of CVD risk markers,
including insulin resistance, inflammation, renal function
and NT-proBNP.
Table 3 Incidence rates/1000
person-years and adjusted HRs
(95% CIs) for CVD endpoints by
copeptin levels in 428 men with
prevalent diabetes and no heart
failure
Incidence Copeptin (pmol/l)a 1 unit increase
in loge copeptin
p trend
<3.35
(n = 143)
3.35–6.95
(n= 142)
≥6.96
(n = 143)
CHD (n= 67)
Rate/1000
person-years (n)
12.5 (20) 13.6 (19) 22.5 (28)
Age-adjusted HR 1.00 1.11 (0.59, 2.05) 1.85 (1.04, 3.29) 1.17 (0.86, 1.59) 0.33
Model 1 1.00 0.95 (0.49, 1.82) 1.59 (0.83, 3.04) 1.02 (0.77, 1.36) 0.88
Model 2 1.00 0.88 (0.45, 1.73) 1.21 (0.60, 2.42) 0.94 (0.72, 1.22) 0.63
Model 3 1.00 0.86 (0.43, 1.68) 1.18 (0.59, 2.35) 0.94 (0.73, 1.20) 0.59
Model 3a 1.00 0.76 (0.36, 1.60) 0.99 (0.47, 2.09) 1.00 (0.75, 1.33) 0.99
Stroke (n = 51)
Rate/1000
person-years (n)
7.7 (12) 11.2 (15) 20.5 (24)
Age-adjusted HR 1.00 1.49 (0.70, 3.18) 2.69 (1.34, 5.40) 1.87 (1.29, 2.71) 0.001
Model 1 1.00 1.96 (0.88, 4.36) 2.34 (1.11, 4.91) 1.62 (1.11, 2.37) 0.01
Model 2 1.00 2.11 (0.93, 4.76) 2.22 (1.01, 4.89) 1.63 (1.07, 2.48) 0.02
Model 3 1.00 2.16 (0.93, 4.98) 2.34 (1.04, 5.27) 1.65 (1.06, 2.55) 0.03
Model 3a 1.00 2.03 (0.71, 5.81) 2.97 (1.09, 8.12) 1.73 (0.98, 3.03) 0.05
CVD death (n= 78)
Rate/1000
person-years (n)
10.0 (16) 17.8 (25) 29.7 (37)
Age-adjusted HR 1.00 1.77 (0.94, 3.31) 2.78 (1.54, 4.99) 1.79 (1.33, 2.39) <0.0001
Model 1 1.00 1.67 (0.88, 3.18) 2.99 (1.57, 5.71) 1.62 (1.18, 2.23) 0.003
Model 2 1.00 1.65 (0.86, 3.16) 2.49 (1.27, 4.90) 1.47 (1.06, 2.04) 0.02
Model 3 1.00 1.55 (0.80, 3.03) 2.21 (1.12, 4.36) 1.34 (0.98, 1.84) 0.06
Model 3a 1.00 1.76 (0.80, 3.91) 3.03 (1.39, 6.62) 1.92 (1.23, 2.98) 0.004
a Cut-offs based on the tertile distribution in men with diabetes
Model 1: adjusted for age, smoking, heavy drinking, physical activity, social class, BMI, HDL-C, systolic BP,
antihypertensive treatment, prevalent MI and prevalent stroke
Model 2: Model 1 +CRP+HOMA-IR+ blood glucose + eGFR
Model 3: Model 2 +NT-proBNP
Model 3a: Model 3, excluding men with prevalent MI/stroke (n= 61; 14.3%)
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Diabetes status, copeptin and CVD Our findings extend
those of a recent report in which copeptin predicted CVD
endpoints in individuals with diabetes only [18]. Vasopressin
levels are increased in patients with diabetes, although the
cause of this is still unclear [10]. Although copeptin has
previously been associated with CVD or stroke in specific
subgroups of patients with diabetes and MI [16] or on
haemodialysis [15], we are not aware of any other studies that
have examined the association between copeptin and stroke in
the general population of older people with diabetes. In this
study, we observed a strong association between copeptin and
stroke events, but not CHD events, after taking into account a
wide range of vascular risk factors and upon exclusion of
those with MI or stroke. We also observed a non-significant
positive association between copeptin and CHD in the
diabetes group. Although the lack of significance in the
diabetes group might be due to small numbers, the positive
association with CHD was markedly attenuated upon
exclusion of those with MI or stroke, and a similar pattern of
attenuation was also seen in participants without diabetes.
Thus the increased risk of CHD associated with copeptin seen
in both the diabetic and non-diabetic groups appears to be
largely due to pre-existing CVD. This is consistent with
previous reports that have shown copeptin to predict CVD
specifically in those with coronary artery disease [33, 34].
Similar findings have also been reported in the German
Diabetes and Dialysis Study, in which copeptin predicted
stroke but not MI in diabetes patients undergoing
haemodialysis [15]. In the Malmo Diet and Cancer Study
[18] a positive association was seen with CHD in the diabetes
group, which included individuals who developed diabetes
during follow-up as well as prevalent diabetes cases. We did
not include incident diabetes in our population of participants
with diabetes. However, when the Malmo Diet and Cancer
Study restricted its analysis to prevalent diabetes only, there
was no association between copeptin and CHD events, similar
to our findings.
Copeptin and risk of major stroke events Brain injury,
including ischaemia, causes the release of stress hormones
such as AVP [35]. It is increasingly being recognised that
copeptin predicts adverse outcomes in patients with stroke
[36]. However, reports on the association between copeptin
and incident stroke in the general population are lacking.
Our findings show that copeptin is associated with the
development of stroke, even in diabetes patients without
prevalent stroke. Whether the relationship between copeptin
and stroke risk in diabetes is causal is uncertain, but it was not
explained by conventional risk factors for stroke, insulin
resistance or NT-proBNP. Renal dysfunction has been
associated with an increased risk of stroke [37] and AVP is
known to be associated with declining kidney function in
patients with diabetes [38]. However, the association between
copeptin and stroke was seen after adjustment for eGFR and
even after the exclusion of men with chronic kidney disease.
Population-based studies have shown copeptin to be strongly
associated with microalbuminuria [39], suggesting a role for
the AVP system in the development of albuminuria, which has
been linked to incident stroke in diabetes as well as in the
general population [39, 40]. This may be a consequence of
the antidiuretic effect of vasopressin, which leads to increased
urinary albumin excretion, an effect mediated by vasopressin
2 receptors [38, 41]. Thus, the association between copeptin,
which is a marker of endogenous vasopressin secretion, and
incident stroke may be linked to increased albuminuria.
Our finding of an association between copeptin and CVD
mortality and stroke events in individuals with diabetes, but
not in those without diabetes, is of potential relevance to
the recent findings of the EMPA-REG OUTCOME trial,
particularly given prior associations of elevated copeptin with
renal and cardiac pathology, heart failure and CVD mortality.
EMPA-REG OUTCOME, which investigated the effects of
the sodium-glucose transporter 2 (SGLT2) inhibitor
empagliflozin on cardiovascular morbidity and mortality in
patients with type 2 diabetes at high cardiovascular risk,
demonstrated a substantial reduction in CVD death and heart
failure hospitalisations with empagliflozin but no effect on
non-fatal CVD events [42]. One may speculate that many
diabetes patients with CVD have subclinical fluid overload,
making them exquisitely sensitive to fluid balance changes.
Notably, SGLT2 inhibitors promote glycosuria by lowering
the renal glucose reabsorption threshold, whereas AVP
promotes water reabsorption through stimulation of V2
receptors, and increased levels of AVP appear to limit
glucose-induced water loss in patients with diabetes [43].
These findings suggest that SGLT2 inhibitors should lessen
copeptin levels in line with improved fluid balance and
cardiac and renal function in diabetes patients with CVD, a
hypothesis that should be directly testable in the near future.
Strengths and limitations The strengths and limitations of
this study require consideration. This is the first study to
examine the association between copeptin and incident stroke
in a general population of older men with and without
diabetes, who constitute a high-risk group for CVD. The
population of the British Regional Heart Study, though
moderate in size, is socially representative of the UK and
follow-up rates are exceptionally high. Ascertainment of
CHD death and MI in this study was based on standard
methods, and both CHD mortality and MI incidence rates
correspond closely with national data. We were able to take
into account a wide range of cardiovascular risk factors,
including markers of inflammation and cardiac markers.
However, our study was based on an older, predominantly
white European, male population, so the results cannot be
generalised directly to women, younger men or other ethnic
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groups; the results therefore need to be substantiated in other
studies and in different population groups. Furthermore, our
findings are based on a single measurement at the baseline
re-examination rather than on repeated assessments, which
may have led to an underestimation of the true strength of
associations. In addition, we did not have information on
microalbuminuria. Although we did not have information on
the type of stroke for all men, 85% of stroke cases in Great
Britain are caused by cerebral ischaemia [44].
Conclusion In this study, we found a significant association
between copeptin and subsequent stroke risk and CVD
mortality in men with diabetes, but not in men without
diabetes, with those with diabetes also having substantially
elevated copeptin levels. Future studies are required to explore
whether elevated copeptin, as a sensitive marker for AVP
secretion, is just a risk marker or a potentially modifiable risk
factor for CVD mortality and stroke in diabetes. The latter
would suggest that suppressing vasopressin with vasopressin
antagonists may have a potential role in reducing stroke and
CVD mortality among individuals with diabetes.
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